Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension dose-ranging study of JNJ-77242113 in moderate-to-severe plaque psoriasis
2021-004320-16Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of icotrokinra in plaque psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoint: PASI 75 response. Started Apr 2022; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2021-004320-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004320-16.